Bicycle Therapeutics plc (BCYC)

Market Cap	915.75M
Revenue (ttm)	41.61M
Net Income (ttm)	-168.16M
Shares Out	42.63M
EPS (ttm)	-4.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,668
Open	22.18
Previous Close	22.18
Day's Range	21.29 - 22.18
52-Week Range	12.54 - 28.91
Beta	0.89
Analysts	Strong Buy
Price Target	47.25 (+121.21%)
Earnings Date	May 2, 2024

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 284
• Stock Exchange: NASDAQ
• Ticker Symbol: BCYC

Financial Performance

In 2023, BCYC's revenue was $26.98 million, an increase of 86.52% compared to the previous year's $14.46 million. Losses were -$180.66 million, 60.3% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for BCYC stock is "Strong Buy." The 12-month stock price forecast is $47.25, which is an increase of 121.21% from the latest price.

Price Target

$47.25

(121.21% upside)

Analyst Consensus: Strong Buy